News Archives - Page 66 of 87

WednesdayNov 16, 2022 1:56 pm

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Gains Alliance Grant Funding, Launches New Program with UBC Professor

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has unveiled a new neurodegenerative disease program (“INM-900 series”). The program will focus on studying the effects of cannabinoid analogs in neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s. Prior to this announcement, InMed had identified potential cannabinoid analogs that exhibited promising effects particularly in relation to the treatment of neurodegenerative diseases; the new program will focus on two lead analogs to conduct studies using in vivo models to select the most appropriate candidate for clinical studies. The company anticipates that early preclinical…

TuesdayNov 15, 2022 2:18 pm

TinyGemsBreaks – Mullen Automotive Inc.’s (NASDAQ: MULN) ‘Strikingly Different’ EV Crossover Tour Takes the Spotlight in Vegas, Heads to Texas

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that it has successfully completed the third stop of the Mullen FIVE Strikingly Different EV Crossover Tour in Las Vegas, Nevada. According to the announcement, Mullen continues onwards to Texas, with stops this week in Dallas and Houston. The Mullen FIVE EV vehicle on tour is equipped with a completely updated infotainment system that features PERSONA, Mullen’s proprietary Personal Vehicle Assistant (“PVA”), which utilizes facial recognition technology to provide every driver with a highly individualized experience. “This tour not only allows the public to see what Mullen has…

TuesdayNov 15, 2022 1:53 pm

TinyGemsBreaks – QSAM Biosciences Inc. (QSAM) Announces Q3 2022 Results, Provides Corporate Update

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam(R)), for the treatment of bone cancer and related diseases, today announced financial results for the third quarter ended Sept. 30, 2022, and provided a corporate update. “Initial, preliminary data from our second patient dosed with CycloSam continues to show positive signals in terms of safety and efficacy. While it is too early for formal conclusions to be made of these results, CycloSam generally performed how we expected it to perform, even given the lowest dosage in our dose-escalating study. This is all very encouraging,” said Douglas R.…

TuesdayNov 15, 2022 1:23 pm

TinyGemsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Q2 Results, Recent Business Highlights, Presentation of CYB003 Preclinical Data at Neuroscience 2022

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), has reported unaudited financial results for its second quarter ended Sept. 30, 2022, as well as recent business highlights. “We have continued to make progress as planned, advancing our clinical pipeline of modified psychedelic-based molecules while also strengthening our drug discovery platform of differentiated preclinical compounds,” said Cybin’s CEO Doug Drysdale. “In addition to our clinical work, we have been actively broadening our robust IP portfolio through securing strategic licensing agreements for preclinical psychedelic-based compounds that will support our ongoing drug development efforts. These recent…

TuesdayNov 15, 2022 11:51 am

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q3 2022 Financial Numbers, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced its Q3 2022 financial report; the company also provided an update regarding its anticancer drug candidates. The report noted that significant progress has been made in CNSP’s key trial designed to study Berubicin’s efficacy in the treatment of recurrent glioblastoma multiforme (“GBM”); that progress includes multiple clinical trial sites being approved for enrollment along with 29 of 68 clinical sites in the United States and Europe already enrolling patients. The company anticipates…

MondayNov 14, 2022 3:34 pm

TinyGemsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Finalized Deal to Provide 40-Plus Machines to NJ University

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”), continues to sign contracts and agreements as it delivers on its mission to provide safety and security to a growing number of organizations around the country. Most recently, Knightscope has signed a contract with a New Jersey university to deliver 31 K1 Blue Light Towers and 10 K1 Blue Light E-Phones. The new contract shows the rising interest that college campuses are showing in Knightscope services. According to the announcement, college safety is a major priority for students when they select which institution to attend. Consequently, colleges and universities…

MondayNov 14, 2022 3:09 pm

TinyGemsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Announces Strategic Move to Sell Alta Mesa Project, Focus on Uranium and Rare Earth Production

Energy Fuels (NYSE American: UUUU) (TSX: EFR), a leading U.S. producer of uranium and rare earth elements (“REE”), today announced its entry into a definitive agreement to sell three wholly owned subsidiaries that together hold its Alta Mesa ISR Project to enCore Energy for total consideration of $120 million (the “transaction”). The transaction, which is expected to close by the end of 2022 or early 2023, is significant for the company, as the cash received is expected to fully finance much of Energy Fuels’ uranium, REE, vanadium and medical isotope business plans for the next two to three years without…

MondayNov 14, 2022 12:55 pm

TinyGemsBreaks – Tingo Inc. (TMNA) Announces Strong Q3 2022 Results, Positioned for Continued Growth and Acceleration of Expansion Strategy

Tingo (OTC: TMNA) today announced that it has filed its quarterly report on Form 10-Q, wherein the company reported its financial results for the three and nine months ended Sept. 30, 2022. Among the highlights, the company reported growth in its Nwassa agri-fintech business that has driven increases of 64.8 % in revenues and 53.9 % in operating profit as compared to Q3 2021. In addition, the company reported that it has filed a definitive Information Statement on Schedule 14C, marking a major milestone towards completion of the merger of Tingo Mobile PLC, the company’s sole operating subsidiary (“Tingo Mobile”),…

MondayNov 14, 2022 12:16 pm

TinyGemsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Partners with 357 Company to Launch Cannabis Division

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is working with the 357 Company to launch 357’s Canna Logistics division. The new division is an expansion beyond 357’s Hemp Logistics segment, which ships federally legal hemp within the United States. According to the announcement, the new division will focus on logistics management and shipping of cannabis and hemp between countries where cannabis has been legalized. 357 is working to expand into international shipping of cannabis, hemp and industrial hemp; the cannabis export/import industry is new and poses significant potential for shipments of…

MondayNov 14, 2022 12:00 pm

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2023 Financial Report, Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has reported its financial results for the first quarter of fiscal year 2023, ended Sept. 30, 2022. Highlights of the report included updates on the company’s pharmaceutical development programs, including INM-755 for the treatment of epidermolysis bullosa (“EB”) and INM-088 for the treatment of glaucoma. According to the report, enrollment and patient treatment in the company’s phase 2 clinical trial for INM-755 should be complete by the end of the year while the company continues to conduct key preclinical work including toxicology and GLP studies in…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

Breaks Categories: News